References
- Barber HRK. Ovarian cancer: diagnosis and management. Am J Ostet Gynecol 1984; 150: 910–916.
- Thigpen TJ, Vance R, Lambuth B et al. Chemotherapy for advanced or recurrent gynecologic cancer. Cancer 1987; 60: 2104–2116.
- Ozols R, Ostchega Y, Curt G et al. High dose carboplatin in refractory cancer patients. J Clin Oncol 1987; 5, 2: 197–201.
- Ozols R, Young C. High dose of cisplatin therapy in ovarian cancer. Sem Oncol 1985; 12, 4: 21–30.
- Alberts DS, Garcia-KendaU D, Survit EA. Phase II trial of mitomycin + 5 FU in the treatment of drug refractory ovarian cancer. Sem Oncol 1988; 15, 3: 22–26.
- Thigpen JT, Vance RP, Balducci L et al. New drugs and experimental approaches in ovarian cancer treatment. Sem Oncol 1984; 11, 3.
- Sutton G, Blessing J, Malfetano J, et al. Phase II trial of ifosfamide and mesna in patients with epithelial ovarian carcinoma resistant to combination chemotherapy. Proc. ASCO 1987; 6: 451.
- Howell SB, Kirmani S, Lucas WE et al. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer. J Clin Oncol 1990; 8, 1: 137–145.
- Falkson G, Van Dik JJ, Van Eden EB et al. A clinical trial on the oral form of 4’demethyl-epipodophyllotoxin-a-D ethylidene glucoside (NSC 141540) VP 16–213. Cancer 1975; 35: 1141–1144.
- Maskens AP, Armand JP, Lacave AJ et al. Phase II clinical trial of VP-16–213 in ovarian cancer. Cancer Treat Rep 1981; 65: 329–330.
- Slayton RE, Creasman WT, Petty W et al. Phase II trial of VP-16–213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a gynecologic oncology group study. Cancer Treat Rep 1979; 63: 2089–2092.
- Thatcher N, Cerny T, Stout R et al. Ifosfamide, etopo-side and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer. Cancer 1987; 60: 2382–2387.
- Miser J, Kinsella T, Tsokos M et al. High response rate of recurrent childhood tumors to etoposide (VP-16), ifosfamide (IFOS) and mesna (MES) uroprotection. Proc ASCO 1986; 5: 820.
- Neijt JP, Van Der Berg MEL, Vriesendorp R et al. Randomized trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984; 2: 594–600.
- Briscoe K, Pasmantier M, Brown J et al. Cisdiammine-dichloroplatinum (II) and adriamycin treatment of advanced ovarian cancer. Proc Am Assoc Cancer Res and ASCO 1978; 19: 378.
- Neijt JP, Ten Bokkel Huinink WW, Hamerama B et al. Combination chemotherapy including cisplatinum in previously treated patients with advanced ovarian carcinoma. Proc ASCO 1982; 23: 108.